TEVA Overview

Teva Pharmaceutical Industries Ltd is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.

Wall Street analysts forecast TEVA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TEVA is35.71 USD with a low forecast of 29.00 USD and a high forecast of 40.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Teva Pharmaceutical Industries Ltd revenue for the last quarter amounts to 4.72B USD, increased 12.61

Teva Pharmaceutical Industries Ltd. EPS for the last quarter amounts to 0.41 USD, decreased -315.79

Teva Pharmaceutical Industries Ltd (TEVA) has 31173 emplpoyees as of March 31 2026.

Today TEVA has the market capitalization of 33.02B USD.